VitaNova Life Sciences (VNOV) Current Deferred Revenue (2025)
VitaNova Life Sciences' (VNOV) quarterly Current Deferred Revenue came in at $4286.0 in Q4 2025, down 60.22% on a QoQ basis from $10775.0 in Q3 2025.
Powered by 
Analysis
VitaNova Life Sciences (VNOV) Current Deferred Revenue (2025) Analysis & Trends
VitaNova Life Sciences has disclosed Current Deferred Revenue across 1 years of filings, most recently posting $4286.0 for Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Accenture | 120.96 Bn | 111.91 Bn | 6.13 Bn |
| 2 | UL Solutions | 12.94 Bn | 12.53 Bn | 417.00 Mn |
| 3 | Gartner | 11.74 Bn | 10.25 Bn | 1.19 Bn |
| 4 | Booz Allen Hamilton Holding | 9.28 Bn | 8.74 Bn | 1.46 Bn |
| 5 | Tetra Tech | 9.14 Bn | 8.91 Bn | 243.21 Mn |
| 6 | Genpact | 5.74 Bn | 5.22 Bn | 490.34 Mn |
| 7 | Grand Canyon Education | 3.97 Bn | 3.69 Bn | 204.08 Mn |
| 8 | Fti Consulting | 3.91 Bn | 3.74 Bn | 316.27 Mn |
| 9 | Korn Ferry | 3.90 Bn | 3.09 Bn | 681.29 Mn |
| 10 | VitaNova Life Sciences | 11.51 Mn | 9.90 Mn | 30,521.00 |